Hyphens is currently licensing sugar-based surfactant micro-emulsions technology from A*STAR’s Institute of Chemical and Engineering Sciences (ICES). By leveraging A*STAR’s research and development capabilities, it is envisioned that this MoU will enable Hyphens to develop innovative and differentiated dermatological products to address unmet market needs.

Hyphens is a Singapore-headquartered ASEAN specialty pharma company. Operating in six countries across the region, Hyphens has a strong medical, regulatory and commercial capability. Dermatology is a key therapeutic focus field where Hyphens markets products under the brands “Ceradan” and “TDF”.

We successfully achieved full house for two of our supported symposiums delivered by key speakers from Germany and Singapore. The first symposium was on the advancement in atopic dermatitis and COPES, featuring our study in collaboration with KK Women’s and Children’s Hospital and National Skin Centre (Ceradan®). The second symposium was on urticaria and the clinical relevance of PAF (Rupafin®).